Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27092921 | 1.00 | IKZF2 (0.59) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL30798405 | 1.00 | IKZF2 (0.59) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL29152454 | 0.90 | IKZF2 (0.59) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL30798426 | 0.90 | IKZF2 (0.59) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL24718027 | 0.90 | IKZF2 (0.59) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL24717991 | 0.89 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL30798487 | 0.89 | IKZF2 (0.50) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL30798631 | 0.88 | IKZF2 (0.47) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL24717737 | 0.88 | IKZF2 (0.47) | IKZF2IKZF1CRBNIKZF3BRD4 | |
| SCHEMBL24717997 | 0.87 | IKZF2 (0.45) | IKZF2IKZF1CRBNIKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4323352-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986532-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | IKZF2 50/4885IKZF1 57/4885CRBN 4/4885 |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | IKZF2 50/4885IKZF1 57/4885CRBN 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.